Quoted from http://online.wsj.com/article/BT-CO-20090914-709952.html
Two New Cases Of PML Found In Tysabri MS Patients
SEPTEMBER 14, 2009, 12:26 P.M. ET
By Thomas Gryta Of DOW JONES NEWSWIRES
NEW YORK (Dow Jones)--Two more cases of a rare brain infection have emerged in users of the multiple-sclerosis drug Tysabri, sold by Biogen Idec Inc. (BIIB) and Elan Plc (ELN), the first such incidences since Biogen stopped updating investors of the situation in July.
At that time, Biogen had confirmed 11 cases of progressive multifocal leukoencephalopathy, or PML, since the drug's relaunch in July 2006; Tysabri was pulled from the U.S. market in 2005 because of PML concerns.
A Biogen spokeswoman said the Cambridge, Mass., biotech is neither commenting on nor confirming the existence of additional cases as long as the PML rate is consistent with the rate of one-in-1,000 patients implied by the label. The new cases appear to be in line with the label's rate.
An editorial published in the New England Journal of Medicine last week revealed a new case that occurred in Europe.
The latest case, also in Europe, was confirmed by Ralf Gold of the Ruhr University Bochum, Germany, who presented the case at the European Committee for Treatment and Research in Multiple Sclerosis that ended Saturday.